SRRA - Sierra Oncology completes enrollment in late-stage myelofibrosis study

Nano-cap Sierra Oncology (SRRA) announces the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic.The study enrolled 195 patients based on a planned 180 patients across 21 countries.The company expects to post topline data from the study in Q1 2022, and intends to file a New Drug Application ((NDA)) with the U.S. FDA in H2 2022.The company had provided updated overall survival ((OS)) data for momelotinib from Phase 3 studies in myelofibrosis patients, in December last year.

For further details see:

Sierra Oncology completes enrollment in late-stage myelofibrosis study